Get the Stockscreener App
1.56
0.64%
-0.01
Brainstorm Cell Therapeutics Inc stock is traded at $1.56, with a volume of 9,533.
It is down -0.64% in the last 24 hours and down -13.33% over the past month.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
See More
Previous Close:
$1.57
Open:
$1.58
24h Volume:
9,533
Relative Volume:
0.15
Market Cap:
$8.90M
Revenue:
-
Net Income/Loss:
$-16.63M
P/E Ratio:
-3.6279
EPS:
-0.43
Net Cash Flow:
$-21.84M
1W Performance:
-1.89%
1M Performance:
-13.33%
6M Performance:
-63.12%
1Y Performance:
-68.54%
1-Day Range:
$1.55
$1.69
1-Week Range:
$1.55
$1.6999
52-Week Range:
$1.05
$11.89
Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile
Name
Brainstorm Cell Therapeutics Inc
Sector
Industry
Phone
201-488-0460
Address
1325 AVENUE OF AMERICAS, NEW YORK, NY
Compare BCLI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCLI
Brainstorm Cell Therapeutics Inc
|
1.56 | 8.90M | 0 | -16.63M | -21.84M | -0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-21 | Upgrade | Maxim Group | Hold → Buy |
| Nov-17-20 | Downgrade | Maxim Group | Buy → Hold |
| Dec-19-16 | Reiterated | Maxim Group | Buy |
| Dec-22-15 | Reiterated | Maxim Group | Buy |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Latest News
INVESTOR ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
StockNews.com Begins Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI) - Defense World
Brainstorm Cell Therapeutics Inc. to Host Earnings Call - ACCESS Newswire
Brainstorm Cell Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Expands By 21.3% - Defense World
Innovations in Stem Cell Therapy Market: Transforming - openPR
INVESTOR ALERT: Levi & Korsinsky Reminds Brainstorm Cell Therapeutics Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024BCLI - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Brainstorm Cell Therapeutics Inc. (BCLI) Investigation - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineBCLI - ACCESS Newswire
5 Best Stem Cell Companies to Invest In (March 2025) - Securities.io
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated by Analysts at StockNews.com - Defense World
INVESTOR ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineBCLI - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Brainstorm Cell Therapeutics Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024BCLI - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Brainstorm Cell Therapeutics Inc.(BCLI) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Adaptive Biotechnologies (NASDAQ:ADPT) versus Brainstorm Cell Therapeutics (NASDAQ:BCLI) Financial Comparison - Defense World
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com - Defense World
StockNews.com Initiates Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI) - Defense World
Amyotrophic Lateral Sclerosis (ALS) Market Future Prospects, - openPR
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Upgraded by StockNews.com to Hold Rating - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces Brainstorm Cell Therapeutics Inc. (BCLI) Investigation - ACCESS Newswire
Brainstorm Cell Therapeutics Appeals Nasdaq Delisting - MSN
Brainstorm Cell Therapeutics Appeals Nasdaq Delisting By Investing.com - Investing.com Australia
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Upgraded to “Hold” at StockNews.com - Defense World
Amyotrophic Lateral Sclerosis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Treatment Outlook | Biogen, GSK, Helixmith, Sanofi, Denali Therapeutics, Ionis Pharma, Brainstorm Cell - The Globe and Mail
Brainstorm Cell Therapeutics faces Nasdaq delisting By Investing.com - Investing.com Nigeria
Brainstorm Cell Therapeutics faces Nasdaq delisting - Investing.com
BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting - GuruFocus.com
StockNews.com Downgrades Brainstorm Cell Therapeutics (NASDAQ:BCLI) to Sell - Defense World
Mesenchymal Stem Cells Market Outlook 2024: Emerging Trends and Regulatory Shifts Shaping the Future - WICZ
Global Stem Cell Characterization and Analysis Tool Market Size - WICZ
Equities Analysts Offer Predictions for BCLI FY2024 Earnings - Defense World
BCLI: Plans Coming Together for Phase 3b Trial of NurOwn in ALS - Smartkarma
BCLI: Plans Coming Together for Phase 3b Trial of NurOwn® in ALS… - MSN
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program - GuruFocus.com
BrainStorm Cell Therapeutics Announces Key Milestones and Strategic Plans for ALS Therapy NurOwn® - Tandav Media
BrainStorm Cell Advances NurOwn ALS Treatment with FDA Special Protocol Assessment and Manufacturing Deal - StockTitan
BrainStorm Issues 2024 Letter to Shareholders - PR Newswire
BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update - The Eastern Progress Online
BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024 - The Eastern Progress Online
Amyotrophic Lateral Sclerosis (ALS) Market: Segmentation - openPR
BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Kilgore News Herald
Autologous Cell Therapy Market Expected to Grow at Rapid Rates - openPR
BrainStorm secures patent for exosome technology By Investing.com - Investing.com Nigeria
BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology - Lelezard
Brainstorm Cell Therapeutics Inc Stock (BCLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Brainstorm Cell Therapeutics Inc Stock (BCLI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lebovits Chaim | President & CEO |
Sep 30 '24 |
Buy |
0.23 |
22,000 |
5,016 |
1,186,865 |
| Dagher Ibrahim B. | Chief Medical Officer |
Jul 19 '24 |
Sale |
0.35 |
63,000 |
22,069 |
0 |
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):